+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of a udp glucose 4 epimeraseless mutant of salmonella typhi as a live oral vaccine

Evaluation of a udp glucose 4 epimeraseless mutant of salmonella typhi as a live oral vaccine

Journal of Infectious Diseases 136(6): 717-723

A mutant (Ty21a) of S. typhi, which lacks the enzyme UDP glucose-4-epimerase, was evaluated in volunteers for use as a live attenuated oral typhoid vaccine. Five to 8 doses of vaccine (containing 3-1010 viable organisms/dose) were given to 155 men without significant side effects. The rate of excretion of the vaccine strain in stools was low and the majority of isolations occurred on day 1 after vaccination. Revertants able to ferment galactose were not found in any of 958 stool isolates tested. The mutant, strain Ty21a, grown in brain-heart infusion broth (BHIB) with 0.1% galactose, produces more O side chain than the same vaccine strain cultivated without galactose. Volunteers vaccinated with strain Ty21a grown in galactose and then challenged with 105 virulent S. typhi were significantly protected from disease and also had decreased stool carriage of S. typhi as compared with controls. Strain Ty21a grown without galactose did not provide vaccinees significant protection nor decrease fecal excretion of S. typhi as compared with controls. Strain Ty21a, when grown in BHIB with 0.1% galactose, results in a safe, stable and protective oral vaccine that warrants further study in field trials.

(PDF 0-2 workdays service: $29.90)

Accession: 005395828

Download citation: RISBibTeXText

PMID: 925379

Related references

Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. Journal of Infectious Diseases 131(5): 553-558, 1975

Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. Journal of Clinical Investigation 90(2): 412-420, 1992

Phase I clinical evaluation of live oral vaccine candidate Salmonella typhi PBCC211. Abstracts of the General Meeting of the American Society for Microbiology 95(0): 295, 1995

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24(2): 116-123, 2005

Enteroadhesion fimbriae and enterotoxin of Escherichia coli: genetic transfer to a streptomycin-resistant mutant of the galE oral-route live-vaccine Salmonella typhi Ty21a. Infection and Immunity 50(3): 925-928, 1985

Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine. 14(1): 4, 1996

Cellular immunity against Salmonella typhi after live oral vaccine. Advances in Experimental Medicine and Biology 216b: 1669-1675, 1987

The rpoS mutant allele of Salmonella typhi Ty2 is identical to that of the live typhoid vaccine Ty21a. FEMS Microbiology Letters 170(1): 141-143, Jan 1, 1999

Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clinical Immunology 138(2): 187-200, 2011

Human cellular immunity against salmonella typhi after live oral vaccine. Federation Proceedings 44(3): 599, 1985

Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?. Vaccine 30(50): 7238-7245, 2013